In the August 27, 2022, the audience was treated to the PREMIER SMARCA4 discussion on the planet, including a mind blowing discussion of 2 patients with stage 4, SMARCA4 deficient non-small cell lung cancers.
The Glasko-Smith-Klein (GSK) pipeline was highlighted, as momelotinib, niraparib, dostarlimab, cobolimab, etc., were discussed. This included their STING agonist, LAG3 inhibitor, etc.
We reviewed the new niraparib neoadjuvant breast cancer data.
MTAP loss was featured as we talked about ways to target it. Novel clinical trials were proposed and SMARCA4 unmet needs were elucidated.
In a truly unprecedented fashion, KRAS inhibitor drug development considerations and concerns were detailed in the context of two stage 4 non-small cell lung cancer patients.
An incredible analysis of the stage 4 SMARCA4 deficient, MTAP loss, and TMB-high, non-small cell lung cancer (NSCLC) patient was performed in the context of the COMET algorithm and treatment cartography. All presently FDA-approved non-small cell lung cancer treatments were discussed, including the data that led to their approval.
Clinical trials in the stage 4 SMARCA 4 deficient and MTAP loss non-small cell lung cancer space were depicted.
NOBODY HAS DONE WHAT WAS DONE IN THIS TUMOR BOARD OR THE THREE PRIOR RCIMTB TUMOR BOARDS. MSK, MD Anderson, Johns Hopkins, Mayo, etc., are not doing what is being done here, but they should be.
If you don't believe that, PLEASE SEE FOR YOURSELF.
This tumor board was hosted by:
Basem S. Goueli MD, PhD, MBA (co-host): CEO and Founder of CancerLight, Cancer Clarity, and Revolution Cancer Medical Care PLLC, medical director for 2 Xbiotech trials, full-time GENERAL hematologist/oncologist, consultant for numerous companies, writer of "The Insider's Guide to Translational Medicine" on biopharmatrend.com and "The Cancer Patients Don't Have an Expiration Date Series" on revolutioncancer.com, author and speaker of the "If You Were My Family Member" cancer patient education series on revolutioncancer.com and this channel
Janakiraman Subramanian MD (co-host): Co-Director of Thoracic Oncology at Inova Schar Cancer Institute (ISCI), and Director for ISCI Data and Analytics Research Core.
Silambarasan Maskomani Ph.D. (co-host): Personalized healthcare ecosystem partner for Roche, where he is currently helping build a precision oncology program in India.
It featured:
Ali Ucar: CEO and co-founder of CaresolutionsUSA
5 сен 2024
